ClinicalTrials.gg
CompletedNCT07769476Updated Aug 18, 2026

Comparison of Clomiphene Alone Versus Clomiphene Plus Sildenafil for Ovulation in Women With Polycystic Ovary Syndrome

A Phase 4 interventional study of Clomiphene Citrate 100 mg and Sildenafil Citrate 25Mg Tab in Polycystic Ovarian Syndrome (PCOS) and Polyendocrine Metabolic Ovarian Syndrome (PMOS), sponsored by Nishtar Medical University. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Nishtar Medical University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jul 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Polycystic Ovary Syndrome with a site in Pakistan — 7 open to participants now, 10 under way, none of them phase 3. Polycystic Ovary Syndrome · Pakistan.

Enrollment
13th of 39
98 · median 70
Started
2025
with 10 others
Phase 4
2 of 40
none open now
Registered
35th of 40
by date
Lead sponsor
3 of 40
Nishtar Medical University

Among the 40 studies in Polycystic Ovary Syndrome with a site in Pakistan, this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2025, is one of 2 in phase 4, and was the 35th registered.

Polycystic Ovary Syndrome

958 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

7 of the 40 studies in Polycystic Ovary Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Polycystic Ovary Syndrome with a site in Pakistan, or all of them as a file.
02

Study summary

The goal of this randomized clinical trial is to compare the effectiveness of clomiphene citrate alone with clomiphene citrate combined with sildenafil citrate for inducing ovulation and achieving pregnancy in women with polycystic ovary syndrome (PCOS) who have difficulty becoming pregnant.

The main question the study aims to answer is:

Does adding sildenafil citrate to clomiphene citrate increase the chance of ovulation and pregnancy compared with clomiphene citrate alone in women with PCOS?

The study will include 98 women aged 18-45 years with PCOS and a history of difficulty achieving pregnancy for more than 2 years. Participants will be randomly assigned to one of two groups.

  • Participants in Group A will receive clomiphene citrate 100 mg once daily from days 3-7 of the menstrual cycle, plus sildenafil citrate 25 mg twice daily from days 8-12.
  • Participants in Group B will receive clomiphene citrate 100 mg once daily from days 3-7, plus a placebo twice daily from days 8-12.

Treatment will be given for 12 weeks. Participants will be assessed for ovulation, pregnancy, and endometrial thickness. Ovulation will be assessed using transvaginal ultrasound and/or a blood progesterone test. Pregnancy will be assessed using a urine pregnancy test and/or ultrasound.

The primary hypothesis is that women receiving clomiphene citrate plus sildenafil citrate will have a higher rate of pregnancy than women receiving clomiphene citrate alone. The study will also determine whether adding sildenafil improves ovulation and endometrial thickness.

03

Conditions studied

  • Polycystic Ovarian Syndrome (PCOS)
  • Polyendocrine Metabolic Ovarian Syndrome (PMOS)

Keywords

  • Clomiphene Citrate
  • Sildenafil Citrate
  • Ovulation Induction
  • Pregnancy
  • Polycystic Ovarian Syndrome
  • Endometrial Thickness
  • Subfertility
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with PCOS,
  • Sub-fertility attributed to PCOS, > 2 years

Exclusion criteria

Exclusion Criteria:

  • Comorbidities; diabetes, hypertension
  • Chronic medical illness (liver, heart, kidney disease)
  • Undergone ovarian drilling
  • Recent administration of hormonal therapy
  • Abnormal prolactin levels (>500 mIU/L), or thyroid function tests (TSH >5.2 mIU/L, T3 \<70 ng/dl and T4 \<5.2 μg/dl)
  • Obstructed fallopian tubes documented on hysterosalpingography and
  • Abnormal semen analysis of their partners
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Clomiphene Citrate + Sildenafil Citrate

    Oral Clomiphene Citrate and Sildenafil Citrate will be given to participants in this Arm

    Drug: Clomiphene Citrate 100 mg · Drug: Sildenafil Citrate 25Mg Tab

  • Placebo comparator
    Clomiphene Citrate + Placebo

    Participants in this arm will be given clomiphene citrate and placebo

    Drug: Clomiphene Citrate 100 mg · Drug: Placebo

Interventions

  • Clomiphene citrate 100 mg administered orally once daily from menstrual cycle days 3-7 for ovulation induction. Treatment will be repeated for 12 weeks.

  • Sildenafil citrate 25 mg administered orally twice daily from menstrual cycle days 8-12, in addition to clomiphene citrate, for ovulation induction. Treatment will be repeated for 12 weeks.

  • DrugPlacebo

    Matching placebo containing starch administered orally twice daily from menstrual cycle days 8-12, in addition to clomiphene citrate. Treatment will be repeated for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Pregnancy

    Pregnancy will be considered achieved when a urine human chorionic gonadotropin (hCG) test is positive after 7 days of a missed menstrual period and/or a gestational sac is detected by ultrasound.

    Time frame: From initiation of treatment (1st cycle) through completion of third treatment cycle, up to 12 weeks

Other outcomes

  1. Ovulation

    Ovulation will be considered present when a collapsed follicle and free fluid in the pouch of Douglas are observed on transvaginal ultrasound and/or serum progesterone is ≥3 ng/mL. Transvaginal ultrasound will be start around cycle day 10-12, then repeat every 1-2 days until evidence of ovulation. Serum progesterone will be measured approximately 7 days after the expected ovulation (often around cycle day 21 in a 28-day cycle).

    Time frame: From initiation of treatment (first cycle) through completion of the third cycle, up to 12 weeks

  2. Endometrial Thickness

    Endometrial thickness will be measured by transvaginal ultrasonography once during each treatment cycle, at the peri-ovulatory assessment when the dominant follicle reaches approximately 18-22 mm in diameter, before evidence of follicular rupture. Measurements will therefore be obtained during each of the three treatment cycles.

    Time frame: From initiation of treatment (first cycle) through completion of the third cycle, up to 12 weeks

07

Study locations

1 site
  • Nishtar Medical University
    Multan, Punjab Province 60000, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

Of 41 non-industry phase 4 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 45. This study's 5 months is below that.

Counting every sponsor, half of 42 studies reached it within 25 months; a quarter within 11 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 18, 2026
StartActual
Jul 1, 2025
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07769476
Lead sponsor
Nishtar Medical University
Responsible party
Asma Ramzan (Principal Investigator, Nishtar Medical University) — Principal investigator
First posted
Aug 18, 2026
Start date
Jul 1, 2025
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Aug 18, 2026

Study contacts

Hajira M Associate Professor, FCPS
study chair · Nishtar Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion